{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT01795313",
            "orgStudyIdInfo": {
                "id": "STUDY19100001"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01CA174858",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01CA174858"
                },
                {
                    "id": "PRO12050422",
                    "type": "OTHER",
                    "domain": "Former IRB protocol ID"
                }
            ],
            "organization": {
                "fullName": "University of Pittsburgh",
                "class": "OTHER"
            },
            "briefTitle": "Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod",
            "officialTitle": "Immunotherapy for Recurrent Ependymomas in Children Using Human Leukocyte Antigen (HLA)-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod",
            "therapeuticArea": [
                "Other"
            ],
            "study": "immunotherapy-for-recurrent-ependymomas-in-children-using-tumor-antigen-peptides-with-imiquimod"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2012-08"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2013-02-12",
            "studyFirstSubmitQcDate": "2013-02-18",
            "studyFirstPostDateStruct": {
                "date": "2013-02-20",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2023-10-31",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "James Felker",
                "investigatorTitle": "Assistant Professor",
                "investigatorAffiliation": "University of Pittsburgh"
            },
            "leadSponsor": {
                "name": "James Felker",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Solving Kids' Cancer",
                    "class": "OTHER"
                },
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined with the immunoadjuvant imiquimod is safe and can induce immune responses in children with recurrent ependymomas. Eligible patients are strati\ufb01ed by primary tumor location."
        },
        "conditionsModule": {
            "conditions": [
                "Ependymoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "This is a pilot study to assess tolerability of our vaccine regimen in children with ependymomas initially arising above or below the tentorium",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 24,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "HLA-A2 restricted tumor antigen vaccine",
                    "type": "EXPERIMENTAL",
                    "description": "This is a single-arm study of a HLA-A2 restricted tumor antigen peptide vaccine, administered in conjunction with imiquimod",
                    "interventionNames": [
                        "Biological: HLA-A2 restricted synthetic tumor antigen",
                        "Drug: Imiquimod",
                        "Other: enzyme-linked immunosorbent assay",
                        "Other: flow cytometry",
                        "Other: immunohistochemistry staining method",
                        "Other: laboratory biomarker analysis"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "HLA-A2 restricted synthetic tumor antigen",
                    "armGroupLabels": [
                        "HLA-A2 restricted tumor antigen vaccine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Imiquimod",
                    "armGroupLabels": [
                        "HLA-A2 restricted tumor antigen vaccine"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "enzyme-linked immunosorbent assay",
                    "armGroupLabels": [
                        "HLA-A2 restricted tumor antigen vaccine"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "flow cytometry",
                    "armGroupLabels": [
                        "HLA-A2 restricted tumor antigen vaccine"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "immunohistochemistry staining method",
                    "armGroupLabels": [
                        "HLA-A2 restricted tumor antigen vaccine"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "laboratory biomarker analysis",
                    "armGroupLabels": [
                        "HLA-A2 restricted tumor antigen vaccine"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants with unacceptable toxicity",
                    "description": "Grade 3 or 4 non-hematological toxicities.",
                    "timeFrame": "2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Tumor-associated antigen-specific T-cell",
                    "timeFrame": "2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria: All grades of ependymoma are eligible.\n\n* Patients must have recurrent/progressive ependymoma that has progressed or recurred after initial adjuvant therapy.\n* HLA-A2 positive based on flow cytometry performed at the University of Pittsburgh.\n* Patients must have previously received standard initial therapy including attempted gross total resection, where safely feasible, and in appropriate circumstances (e.g., those older than one year at initial diagnosis, with non-metastatic tumors and at least microscopic residual disease), involved field fractionated radiation therapy (RT). Patients may have received re-irradiation but not to the index lesion within 4 weeks.\n* Patients must be clinically stable and off or on low-dose (no more than 0.1 mg/kg/day, max 4 mg/day Dexamethasone) corticosteroid for at least one week prior to study registration.\n* Patients must be \u2265 12 months and \\<22 years of age at the time of study registration.\n* Patients must have a performance status of \u2265 70; (Karnofsky if \\> 16 years and Lansky if \u2264 16 years of age).\n* Patients may have non-bulky, asymptomatic metastatic disease.\n* Males and females must agree to use effective birth control methods during the course of vaccination (from the first vaccine to two weeks after the last vaccine).\n* Patients must be free of systemic infection requiring IV antibiotics at the time of registration and off IV antibiotics for at least 7 days prior to registration.\n* Patients must have adequate organ function as measured by:\n\n  * Bone marrow: Absolute neutrophil count (ANC) \\> 1,000/\u00b5l; Platelets \\> 100,000/\u00b5l (transfusion independent); Absolute lymphocyte count (ALC) \u2265 500/\u00b5l; Hemoglobin \\>8 g/dl (may be transfused).\n  * Hepatic: bilirubin \u2264 1.5x institutional normal for age; serum glutamate pyruvate transaminase (SGPT) \\< 3x institutional normal\n  * Renal: Serum creatinine based on age or creatinine clearance or radioisotope glomerular filtration rate (GFR) \\> 70 ml/min/1.73 m\u00b2\n* Patients must have recovered from the toxic effects of prior therapy and be at least 3 weeks from the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy, at least one week from the last dose of non-myelosuppressive biological therapy and at least 4 weeks from the completion of radiation therapy.\n* Patients must have no overt cardiac, gastrointestinal, pulmonary, or psychiatric disease.\n\nPatients must be willing to travel to Pittsburgh to receive the vaccine. Visits: Every 3 weeks x 9, then every 6 weeks x 12 depending on response/side effects\n\nExclusion Criteria:\n\n* Patients living outside of North America are not eligible.\n* Patients must be off concurrent treatment or medications for at least 1 week including: Interferon (e.g. Intron-A\u00ae), allergy desensitization injections, growth factors (e.g. Procrit\u00ae, Aranesp\u00ae, Neulasta\u00ae), interleukins (e.g. Proleukin\u00ae), and any investigational therapeutic medication.\n* Patients must not have a history of any immune system disorder or laboratory abnormality or any condition that could potentially alter immune function.\n* Use of immunosuppressives within four weeks prior to study entry or anticipated use of immunosuppressive agents. Patients must be on no more than 0.1 mg/kg/day, max 4 mg/day dexamethasone for at least one week before study registration. Topical corticosteroids are acceptable.\n* Patients with a known immune deficiency.\n* Pregnancy or breastfeeding. Female patients who are post-menarchal must have a documented negative pregnancy test.\n* Tetanus vaccine during therapy or within 1 week prior to enrollment.\n* Patients who have received prior immunotherapy.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "12 Months",
            "maximumAge": "21 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "James Felker, MD",
                    "role": "CONTACT",
                    "phone": "412-692-5055"
                },
                {
                    "name": "Sharon Dibridge",
                    "role": "CONTACT",
                    "phone": "412-692-7070",
                    "email": "sharon.dibridge@chp.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "James Felker, MD",
                    "affiliation": "University of Pittsburgh",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Children's Hospital of Pittsburgh of UPMC",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15224",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sharon Dibridge",
                            "role": "CONTACT",
                            "phone": "412-692-7070",
                            "email": "sharon.dibridge@chp.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000004806",
                    "term": "Ependymoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005910",
                    "term": "Glioma"
                },
                {
                    "id": "D000018302",
                    "term": "Neoplasms, Neuroepithelial"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M7965",
                    "name": "Ependymoma",
                    "asFound": "Ependymoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9020",
                    "name": "Glioma",
                    "relevance": "LOW"
                },
                {
                    "id": "M20446",
                    "name": "Neoplasms, Neuroepithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "T2093",
                    "name": "Ependymoma",
                    "asFound": "Ependymoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2519",
                    "name": "Glioma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077271",
                    "term": "Imiquimod"
                }
            ],
            "ancestors": [
                {
                    "id": "D000097912",
                    "term": "Toll-Like Receptor Agonists"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000091369",
                    "term": "Immunomodulating Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000276",
                    "term": "Adjuvants, Immunologic"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000007369",
                    "term": "Interferon Inducers"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M17360",
                    "name": "Vaccines",
                    "relevance": "LOW"
                },
                {
                    "id": "M1727",
                    "name": "Imiquimod",
                    "asFound": "Host",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M3628",
                    "name": "Adjuvants, Immunologic",
                    "relevance": "LOW"
                },
                {
                    "id": "M10407",
                    "name": "Interferons",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}